Ken Griffin’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $388K | Sell |
808
-58,932
| -99% | -$30.2M | ﹤0.01% | 9877 |
|
|
2025
Q4 | $33.6M | Buy |
59,740
+36,827
| +161% | +$20.9M | 0.01% | 1797 |
|
|
2025
Q3 | $11.8M | Sell |
22,913
-46,089
| -67% | -$20.1M | ﹤0.01% | 3019 |
|
|
2025
Q2 | $21.7M | Buy |
+69,002
| New | +$20.7M | ﹤0.01% | 2042 |
|
|
2025
Q1 | – | Sell |
-8,107
| Closed | -$2.73M | – | 15149 |
|
|
2024
Q4 | $2.69M | Sell |
8,107
-8,145
| -50% | -$2.76M | ﹤0.01% | 5025 |
|
|
2024
Q3 | $5.42M | Buy |
16,252
+6,597
| +68% | +$2.51M | ﹤0.01% | 3805 |
|
|
2024
Q2 | $3.98M | Sell |
9,655
-83,736
| -90% | -$33.2M | ﹤0.01% | 4111 |
|
|
2024
Q1 | $37.7M | Buy |
93,391
+87,313
| +1,437% | +$30.7M | 0.01% | 1443 |
|
|
2023
Q4 | $1.86M | Sell |
6,078
-31,178
| -84% | -$8.42M | ﹤0.01% | 5486 |
|
|
2023
Q3 | $9.02M | Sell |
37,256
-35,159
| -49% | -$8.99M | ﹤0.01% | 2818 |
|
|
2023
Q2 | $17.4M | Buy |
72,415
+70,271
| +3,278% | +$14.6M | ﹤0.01% | 2031 |
|
|
2023
Q1 | $403K | Sell |
2,144
-41,965
| -95% | -$8.68M | ﹤0.01% | 8755 |
|
|
2022
Q4 | $9.37M | Buy |
44,109
+41,354
| +1,501% | +$8.26M | ﹤0.01% | 2926 |
|
|
2022
Q3 | $433K | Sell |
2,755
-10,219
| -79% | -$1.63M | ﹤0.01% | 8783 |
|
|
2022
Q2 | $1.94M | Buy |
12,974
+4,911
| +61% | +$711K | ﹤0.01% | 5607 |
|
|
2022
Q1 | $1.32M | Sell |
8,063
-21,917
| -73% | -$3.61M | ﹤0.01% | 7059 |
|
|
2021
Q4 | $6.53M | Buy |
29,980
+27,437
| +1,079% | +$5.75M | ﹤0.01% | 3836 |
|
|
2021
Q3 | $481K | Buy |
+2,543
| New | +$464K | ﹤0.01% | 9969 |
|
|
2021
Q2 | – | Sell |
-22,230
| Closed | -$3.84M | – | 14094 |
|
|
2021
Q1 | $3.65M | Sell |
22,230
-19,356
| -47% | -$2.96M | ﹤0.01% | 4991 |
|
|
2020
Q4 | $5.79M | Buy |
41,586
+12,763
| +44% | +$1.61M | ﹤0.01% | 3433 |
|
|
2020
Q3 | $3.22M | Buy |
28,823
+22,629
| +365% | +$2.62M | ﹤0.01% | 3865 |
|
|
2020
Q2 | $576K | Sell |
6,194
-5,538
| -47% | -$471K | ﹤0.01% | 6817 |
|
|
2020
Q1 | $861K | Buy |
+11,732
| New | +$1.02M | ﹤0.01% | 5598 |
|
|
2019
Q3 | – | Sell |
-7,101
| Closed | -$537K | – | 9534 |
|
|
2019
Q2 | $464K | Sell |
7,101
-13,511
| -66% | -$779K | ﹤0.01% | 6940 |
|
|
2019
Q1 | $1.22M | Buy |
20,612
+1,987
| +11% | +$119K | ﹤0.01% | 5238 |
|
|
2018
Q4 | $986K | Sell |
18,625
-307,083
| -94% | -$16.9M | ﹤0.01% | 5330 |
|
|
2018
Q3 | $19.5M | Buy |
325,708
+158,502
| +95% | +$8.67M | 0.01% | 1412 |
|
|
2018
Q2 | $7.19M | Buy |
167,206
+161,099
| +2,638% | +$6.51M | ﹤0.01% | 2299 |
|
|
2018
Q1 | $213K | Sell |
6,107
-2,511
| -29% | -$91.7K | ﹤0.01% | 7263 |
|
|
2017
Q4 | $312K | Sell |
8,618
-13,515
| -61% | -$474K | ﹤0.01% | 6398 |
|
|
2017
Q3 | $706K | Buy |
22,133
+15,213
| +220% | +$465K | ﹤0.01% | 4828 |
|
|
2017
Q2 | $201K | Sell |
6,920
-24,276
| -78% | -$681K | ﹤0.01% | 6562 |
|
|
2017
Q1 | $931K | Buy |
+31,196
| New | +$1.01M | ﹤0.01% | 4113 |
|
|
2016
Q4 | – | Sell |
-52,162
| Closed | -$1.56M | – | 7609 |
|
|
2016
Q3 | $1.56M | Buy |
+52,162
| New | +$1.52M | ﹤0.01% | 3257 |
|
Other funds holding MEDP
VPM
VCM
WA
Ken Griffin's MEDP Position: Q1 2026 in Review
Ken Griffin reduced its Medpace (MEDP) stake by 99% in Q1 2026, selling an estimated $30.2M and leaving 808 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #9877.
Ken Griffin first reported a position in MEDP in Q3 2016 and has held it in 34 quarters since. The position peaked at $37.7M in Q1 2024. 731 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.
- Ken Griffin held 808 shares of Medpace worth $388K as of Q1 2026.
- Ken Griffin sold 58,932 Medpace shares in Q1 2026, an estimated $30.2M.
- Medpace made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #9877 holding.
- Ken Griffin first reported a position in Medpace in Q3 2016 and has held it in 34 quarters since.
- Ken Griffin's Medpace position peaked at $37.7M in Q1 2024.
- 731 funds tracked by Wall St. Rank held Medpace as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.